This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
A practical intro to yield programs for USDC, focusing on how to earn with confidence and manage associated risks. Learn the basics and start optimizing today.
12,846 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Investors woke up to another sharp move in a small-cap space contractor. This article breaks down why intuitive machi...
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Starbucks CEO Brian Niccol says the company drifted into factory-like operations. He outlines a reset designed to rec...
In stock market today, march, Grab surprised investors with a substantial buyback and a bold Foodpanda expansion. Thi...
Washington moves to outlaw noncompete agreements statewide, imposing a 2027 deadline. The sweeping policy reshapes hi...
GameStop is weighing a bold move: acquiring eBay. This article breaks down whether does Gamestop's proposed acquisiti...
Vericel faces a pivotal 2026 earnings season. This guide breaks down the drivers behind the numbers, what to watch in...
A civil social-media debate this spring highlighted a looming fight over who will own payments: Visa or on-chain stab...
Real Brokerage deepens its Kansas City presence by adding Chartwell Realty, bringing 150 agents and cementing its sta...
Colgate-Palmolive posted stronger-than-expected Q1 2026 results, setting the stage for upside despite tariff headwind...
A sweeping study ties two decades of bat die-offs to rising crop damages, heavier local taxes, and pricier debt for r...